BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miquelestorena-standley E, Tallet A, Collin C, Piver E, De Muret A, Salamé E, Bourlier P, Kervarrec T, Guyétant S, Pagès J. Interest of variations in microRNA-152 and -122 in a series of hepatocellular carcinomas related to hepatitis C virus infection: MicroRNA in hepatocellular carcinoma. Hepatol Res 2018;48:566-73. [DOI: 10.1111/hepr.12915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res. 2019;49:531-539. [PMID: 30577089 DOI: 10.1111/hepr.13304] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 15.7] [Reference Citation Analysis]
2 Morishita A, Masaki T. MicroRNAs as possible biomarkers for hepatocellular carcinoma: MiRNAs as biomarkers for HCC. Hepatol Res 2018;48:499-501. [DOI: 10.1111/hepr.13078] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
3 Kohno T, Morishita A, Iwama H, Fujita K, Tani J, Takuma K, Nakahara M, Oura K, Tadokoro T, Nomura T, Yoneyama H, Kato K, Okano K, Suzuki Y, Nishiyama A, Himoto T, Masaki T. Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. Oncol Lett 2020;20:1727-33. [PMID: 32724415 DOI: 10.3892/ol.2020.11696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Dai M, Li L, Qin X. Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer. Oncol Lett 2019;17:3919-29. [PMID: 30881509 DOI: 10.3892/ol.2019.10024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
5 Yin T, Liu MM, Jin RT, Kong J, Wang SH, Sun WB. miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8. Pathol Res Pract 2019;215:152406. [PMID: 30967300 DOI: 10.1016/j.prp.2019.03.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
6 El-Araby RE, Khalifa MA, Zoheiry MM, Zahran MY, Rady MI, Ibrahim RA, El-Talkawy MD, Essawy FM. The interaction between microRNA-152 and DNA methyltransferase-1 as an epigenetic prognostic biomarker in HCV-induced liver cirrhosis and HCC patients. Cancer Gene Ther 2020;27:486-97. [PMID: 31316135 DOI: 10.1038/s41417-019-0123-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]